Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Monopar Therapeutics Inc. filed a current report to share that it presented clinical trial results at a major medical conference. On May 29, 2026, the company presented results from a Phase 2 study (NCT04422431) of ALXN1840 (tiomolibdate choline) in patients with Wilson disease at the European Association for the Study of the Liver International Liver Congress 2026.
The related scientific presentation is furnished as Exhibit 99.1 and is incorporated by reference, providing more detailed information on the Phase 2 study’s evaluation of liver pathology and clinical symptoms in Wilson disease.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
Regulation FD Disclosure, Phase 2 study, ALXN1840 (tiomolibdate choline), Wilson disease, +1 more
5 terms
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure On May 29, 2026, Monopar Therapeutics Inc."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Phase 2 study financial
"presented results from a Phase 2 study (NCT04422431) evaluating the effect of ALXN1840"
A phase 2 study is a mid-stage clinical trial that tests whether an experimental drug or treatment actually works for the intended condition and continues to check safety in a larger group of patients than early trials. Think of it as a focused pilot test before a full market launch; positive or negative results strongly affect a drug’s chances of approval, the remaining development time and costs, and therefore an investment’s risk and potential value.
ALXN1840 (tiomolibdate choline) medical
"Phase 2 study (NCT04422431) evaluating the effect of ALXN1840 (tiomolibdate choline) on liver pathology"
Wilson disease medical
"clinical symptoms in patients with Wilson disease at the European Association for the Study of the Liver"
A genetic disorder that prevents the body from removing excess copper, causing copper to build up mainly in the liver and brain and leading to liver disease, movement problems, and cognitive or psychiatric symptoms. Investors pay attention because tests, drugs, gene therapies or diagnostic tools for this condition can drive regulatory approvals, clinical trial risk, and niche market opportunities; think of it as a small but high-need market where a successful treatment can meaningfully change company value.
Inline XBRL technical
"Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2026
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(847 ) 388-0349
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure
On May 29, 2026, Monopar Therapeutics Inc. (“Monopar”) presented results from a Phase 2 study (NCT04422431) evaluating the effect of ALXN1840 (tiomolibdate choline) on liver pathology and clinical symptoms in patients with Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2026.
The presentation is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Presentation dated May 29, 2026.
|
|
|
104
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Monopar Therapeutics Inc.
|
|||
|
Date: May 29, 2026
|
By:
|
/s/ Quan Vu
|
|
|
Name:
|
Quan Vu
|
||
|
Title:
|
Chief Financial Officer
|
||
Exhibit 99.1
FAQ
What did Monopar Therapeutics (MNPR) disclose in this 8-K filing?
Monopar Therapeutics disclosed that it presented results from a Phase 2 study of ALXN1840 (tiomolibdate choline) in Wilson disease. The results were shared at the EASL International Liver Congress 2026 and detailed in a presentation furnished as Exhibit 99.1.
What clinical study did Monopar Therapeutics (MNPR) present data from?
Monopar presented results from a Phase 2 study identified as NCT04422431. The study evaluated ALXN1840 (tiomolibdate choline) in patients with Wilson disease, focusing on liver pathology and clinical symptoms, with details included in the Exhibit 99.1 presentation dated May 29, 2026.
Where did Monopar Therapeutics (MNPR) present its Phase 2 Wilson disease results?
The company presented the Phase 2 Wilson disease study results at the European Association for the Study of the Liver International Liver Congress 2026. This major liver meeting hosted the presentation on May 29, 2026, with the corresponding slide deck furnished as Exhibit 99.1.
Which drug was evaluated in Monopar Therapeutics’ (MNPR) Phase 2 Wilson disease study?
The Phase 2 study evaluated ALXN1840, also referred to as tiomolibdate choline. Monopar’s report notes that the trial examined this therapy’s effect on liver pathology and clinical symptoms in Wilson disease, with further information contained in the May 29, 2026 presentation.
How can investors access details of Monopar Therapeutics’ (MNPR) Phase 2 results?
Details are available in the presentation furnished as Exhibit 99.1 to the 8-K. This exhibit, dated May 29, 2026, contains the Phase 2 study information on ALXN1840 in Wilson disease and is incorporated by reference into the current report.